HIFU Face-Off: US Competition Begins For Prostate High-Intensity Focused Ultrasound
This article was originally published in The Gray Sheet
Executive Summary
With the 510(k) clearance of EDAP TMS' Ablatherm HIFU and the first US procedure performed with SonaCare Medical's recently cleared Sonablate system, a European rivalry in high-intensity focused ultrasound machines for prostate cancer has moved to the US. And EDAP's CEO argues it was positive for long-term adoption that his firm's system ultimately gained 510(k) clearance as a surgical tool rather than the originally sought PMA approval for a prostate cancer indication.
You may also be interested in...
Final Prostate Ablation Guidance Asks For More Safety Data
Manufacturers developing devices to remove tissue in the prostate should provide the US FDA with follow-up information on patients that include certain indirect data about the long-term safety outcomes of using their product, according to a final agency guidance.
US FDA Asks Prostate Ablation Device-Sponsors For More Clinical Safety Data To Support Clearances
Almost four years after the agency first authorized a prostate ablation device, regulators have proposed a number of requirements for clinical studies that sponsors would have to meet to comply with special controls needed for the devices to be cleared for marketing.
FDA Panel Rejects Sonablate 450 HIFU Device For Prostate Cancer
The advisors voted almost unanimously that SonaCare Medical’s HIFU device did not have good enough data to support a positive risk-benefit profile, but they suggested the company could improve their trial design and try again.